ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
50 announcements with these filters
Ind-Swift Laboratories entered a ₹40 Crore MOU with Him Infratech to build a warehouse facility in Punjab. The project aims to improve storage and operational efficiencies.
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as of June 30, 2026, in compliance with SEBI regulatory requirements.
Ind-Swift Laboratories convened an EGM for August 5, 2026. Key agendas include issuing 70 lakh convertible warrants to promoters and re-appointing an Independent Director.
Ind-Swift Laboratories convened an EGM for August 05, 2026. Agenda includes a Rs. 137.20 Crore preferential warrant issuance to promoter entity Essix Biosciences.
Ind-Swift Laboratories approved a Rs. 137.20 Crore preferential issue of 70 lakh warrants to Essix Biosciences Limited. Warrants are convertible within 18 months.
Ind-Swift Labs will hold a Board Meeting on July 10, 2026, to consider fund raising. Trading window is closed until 48 hours after the meeting.
Ind-Swift Laboratories has re-appointed M/s. V Kumar & Associates as Cost Auditors for a 12-month term. This routine regulatory compliance ensures continued oversight of the company's cost records.
Ind-Swift Laboratories allotted 1,25,000 equity shares under its ESOP 2014 scheme. The company's paid-up share capital increased to 86,96,15,580 shares following this allotment.
Ind-Swift Laboratories allotted 1,25,000 equity shares under its 2014 ESOP scheme. This increases paid-up capital to ₹86.96 Crore, rewarding employees and expanding the share base.
Ind-Swift Laboratories reported zero deviation in the utilization of ₹255.61 Crore raised via preferential warrants. The funds were deployed towards business expansion, investments, and working capital.
Ind-Swift Laboratories Ltd reported revenue from operations of ₹169.8 Cr (+19.2% YoY) and net profit of ₹15.1 Cr (-93.2% YoY) for Q4 FY26.
Ind-Swift Laboratories approved its FY26 audited financial results and re-appointed V. Kumar & Associates as cost auditors. Performance reflects full-year operations post-amalgamation with Ind Swift Limited.
Ind-Swift Laboratories scheduled a board meeting for May 28, 2026, to approve audited financial results. Investors should track the subsequent outcome for performance data.
Ind-Swift Laboratories Limited announced the successful passage of four special resolutions via postal ballot. Shareholders approved the redesignation of Sh. N.R. Munjal and the appointments of Sh. Himanshu Jain and Sh. Sahil Munjal as Managing Directors. Additionally, the payment of remuneration to Whole-Time Director Sh. Rishav Mehta was approved with a requisite majority.
HCP Investments, a non-promoter entity, sold 6,503,423 equity shares of Ind-Swift Laboratories Limited between April 13 and April 17, 2026. This disposal represents 7.5% of the company's total paid-up share capital. Following the transaction, HCP Investments retains a 1.149% stake in the company.
HCP Investments, a non-promoter entity, sold 6,503,423 equity shares of Ind-Swift Laboratories Limited via the open market between April 13 and April 17, 2026. This disposal represents 7.5% of the company's paid-up share capital, reducing HCP's holding to 1.149%.
Ind-Swift Laboratories clarified that the sudden volume spurt in its shares is market-driven. The company noted a recent disclosure on April 7, 2026, regarding a favorable arbitration award from a tribunal rejecting all claims by PI Industries Limited, resulting in NIL financial impact.
Ind-Swift Laboratories Limited clarified to the NSE regarding a sudden spurt in share volume. The company attributed the movement to market factors and a recent disclosure about an arbitration award involving PI Industries Limited, which concluded with nil financial impact.
Ind-Swift Laboratories Ltd received a final arbitration award regarding its dispute with PI Industries Limited. The Arbitral Tribunal rejected all claims and counterclaims from both parties. The proceedings have concluded with nil financial impact on the company, providing legal clarity for investors.
Ind-Swift Laboratories Limited submitted its quarterly compliance certificate under Regulation 74(5) of SEBI Regulations for the period ended March 31, 2026. The registrar, Alankit Assignments Ltd, confirmed that physical share certificates received for dematerialization were processed, cancelled, and substituted with the depository's name.